Search
SOLACI Congress
HomePharmacologyAntithrombotic Anticoagulants

Antithrombotic Anticoagulants

View Category

Antiplatelet

AHA 2025 | OCEAN Study: Anticoagulation vs. Antiplatelet Therapy After Successful Atrial Fibrillation Ablation

After a successful atrial fibrillation (AF) ablation, the need to maintain long-term anticoagulation (AC) remains uncertain, especially...
Dr. Omar Tupayachi -
Learn More
Antithrombotic Anticoagulants

TCT 2025 | STORM-PE: Mechanical Thrombectomy with Penumbra Lightning+AC vs. Anticoagulation Alone in Intermediate-High Risk PE

Intermediate-high risk pulmonary embolism (PE) remains a therapeutic challenge. Anticoagulation is still the standard treatment, albeit with...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

HELP-PCI: A Fleeting Advantage of Early Heparin in ST-Elevation Myocardial Infarction?

In ST-elevation myocardial infarction (STEMI), immediate reperfusion through primary percutaneous coronary intervention (pPCI) remains the treatment of...
Dr. Omar Tupayachi -
Learn More
Antithrombotic Anticoagulants

ESC 2025 | HI-PRO: Extended Apixaban for Recurrence Prevention in Provoked DVT/PE

Patients with provoked venous thromboembolism (VTE) usually discontinue anticoagulation after 3 to 6 months. However, in the...
Dr. Omar Tupayachi -
Learn More
Antithrombotic Anticoagulants

8 Questions About Left Atrial Appendage Closure: Contributions from the 2025 SCAI/HRS Review

Courtesy of Dr. Juan Manuel Pérez. Percutaneous left atrial appendage occlusion (LAAO) is an alternative to oral anticoagulation...
Dr. Juan Manuel Pérez -
Learn More
Antithrombotic Anticoagulants

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will...
Dr. Omar Tupayachi -
Learn More
Antithrombotic Anticoagulants

TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However,...
Dr. Carlos Fava -
Learn More
Acute coronary syndromes

Direct Oral Anticoagulants for Ventricular Thrombus After STEMI

While the incidence of intracavitary thrombi after acute myocardial infarction (AMI) has decreased thanks to optimized primary...
Dr. Omar Tupayachi -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

COILSEAL: Use of Coils in Percutaneous Coronary Intervention, Useful for Complication Management?

Dr. Omar Tupayachi - 0
The use of coils as vascular closing tool has been steadily expanding beyond its traditional role in neuroradiology into coronary territory, where it remains...

Treatment of In-Stent Restenosis in Small Vessels with Paclitaxel-Coated Balloons

Dr. Andrés Rodríguez - 0
Coronary artery disease (CAD) in smaller epicardial vessels occurs in 30% to 67% of patients undergoing percutaneous coronary intervention and poses particular technical challenges....

Contemporary Challenges in Left Atrial Appendage Closure: Updated Approach to Device Embolization

Dr. Juan Manuel Pérez - 0
Even though percutaneous left atrial appendage (LAA) closure is generally safe, device embolization – with 0 to 1.5% global incidence – is still a...

Institutional News

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Watch Again: SELUTION – Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives

solaci - 0
Our webinar “SELUTION: Sirolimus-Eluting Balloon for De Novo Coronary Lesions – New Evidence and Clinical Perspectives”, held on November 19, 2025 via Zoom with...

25/11 – SOLACI Webinar: Pulmonary Embolism in 2025 – Risk Stratification and Novel Therapeutic Approaches

solaci - 0
The Latin American Society of Interventional Cardiology invites you to participate in a new virtual scientific event titled “Pulmonary Embolism (PE) in 2025: Risk...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy